[go: up one dir, main page]

BR112014023092A8 - Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit - Google Patents

Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit

Info

Publication number
BR112014023092A8
BR112014023092A8 BR112014023092A BR112014023092A BR112014023092A8 BR 112014023092 A8 BR112014023092 A8 BR 112014023092A8 BR 112014023092 A BR112014023092 A BR 112014023092A BR 112014023092 A BR112014023092 A BR 112014023092A BR 112014023092 A8 BR112014023092 A8 BR 112014023092A8
Authority
BR
Brazil
Prior art keywords
hpv
immunogenic composition
disease
infection
kit
Prior art date
Application number
BR112014023092A
Other languages
English (en)
Other versions
BR112014023092A2 (pt
Inventor
Desiree Alberte Colau Brigitte
Giannini Sandra
Lockman Laurence
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112014023092A2 publication Critical patent/BR112014023092A2/pt
Publication of BR112014023092A8 publication Critical patent/BR112014023092A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÃO IMUNOGÊNICA, MÉTODO PARA A PREVENÇÃO DE INFECÇÃO OU DOENÇA POR HPV EM UM INDIVÍDUO, E, KIT. A revelação fornece composições imunogênicas compreendendo VLPs do HPV de um ou mais tipos de HPV em combinação com um adjuvante compreendendo um agonista TLR para uso em um método para a prevenção de infecção ou doença por HPV em um indivíduo, em que uma primeira dose da composição imunogênica compreendendo VLPs do HPV e um agonista TLR é administrada, seguida por uma segunda dose de uma composição imunogênica compreendendo VLPs do HPV de um ou mais tipos de HPV, mas que não compreende um agonista TLR.
BR112014023092A 2012-03-18 2013-03-18 Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit BR112014023092A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612345P 2012-03-18 2012-03-18
PCT/EP2013/055582 WO2013139744A1 (en) 2012-03-18 2013-03-18 Method of vaccination against human papillomavirus

Publications (2)

Publication Number Publication Date
BR112014023092A2 BR112014023092A2 (pt) 2017-06-20
BR112014023092A8 true BR112014023092A8 (pt) 2017-07-25

Family

ID=47913410

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023092A BR112014023092A8 (pt) 2012-03-18 2013-03-18 Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit

Country Status (7)

Country Link
US (1) US20150110824A1 (pt)
EP (1) EP2827891A1 (pt)
JP (1) JP2015514696A (pt)
CN (1) CN104203270A (pt)
BR (1) BR112014023092A8 (pt)
CA (1) CA2866582A1 (pt)
WO (1) WO2013139744A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
AU2015335652B2 (en) * 2014-10-24 2020-07-02 Hpvvax, Llc. Cancer and skin lesion treatment
MX2018010338A (es) * 2016-02-27 2018-11-09 Hpvvax Llc Metodo y composicion para tratamiento del cancer o una lesion de la piel utilizando una vacuna.
CA3023968A1 (en) * 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE356142T1 (de) 1991-07-19 2007-03-15 Univ Queensland Impfstoff gegen humanes papillomavirus (typ 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU688759C (en) 1993-03-09 2006-12-21 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
ES2264563T3 (es) 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
US6060324A (en) 1997-11-12 2000-05-09 Phytochem Technologies, Inc. Fluorometric assay composition for measurement of antioxidant activity
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
DE69935330T2 (de) 1998-06-30 2007-10-31 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
EP1719511B1 (en) 2001-11-16 2008-12-10 3M Innovative Properties Company N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
CN1234851C (zh) * 2003-01-30 2006-01-04 上海天甲生物医药有限公司 抗人乳头状瘤病毒疫苗
PE20120563A1 (es) 2009-06-25 2012-05-17 Glaxosmithkline Biolog Sa Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv

Also Published As

Publication number Publication date
BR112014023092A2 (pt) 2017-06-20
CA2866582A1 (en) 2013-09-26
WO2013139744A1 (en) 2013-09-26
CN104203270A (zh) 2014-12-10
JP2015514696A (ja) 2015-05-21
US20150110824A1 (en) 2015-04-23
EP2827891A1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112015010059A2 (pt) terapia adjuvante com inibidor da quinase da família tec
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
UY36422A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
BR212012031500U2 (pt) composições sólidas
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112015004515A2 (pt) composição imunogênica
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014021068A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]